Drug Profile
Glyco 23
Alternative Names: Glyco-23Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Biomedica Management Corporation
- Class Antibacterials; Glycolipids
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Sepsis
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Sepsis in USA (unspecified route) before September 2023
- 28 Aug 2020 No recent reports of development identified for preclinical development in Sepsis in USA
- 15 Jul 2016 Preclinical trials in Sepsis in USA (unspecified route)